A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Type 2 Diabetes Mellitus Patients
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2017
At a glance
- Drugs MK 8666 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co
- 19 Mar 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 12 Feb 2014 Planned End Date changed from 1 Jan 2014 to 1 Feb 2014, as per ClinicalTrials.gov record.
- 13 Jan 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.